$45.60▾ 1.79%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-165.74MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+151.6%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
✦ The read
UroGen Pharma Ltd. is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year. High leverage relative to its assets.
Key numbers
Profitability
Net margin-94.8%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$140.49M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.